
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets.
The company has active engagement in multiple countries spread over three continents. Our lead asset, SkinJect Inc., is a development-stage biotechnology company focused on commercializing a novel treatment for non-melanoma skin cancer, especially basal cell carcinoma (BCC), using a patented dissolvable doxorubicin-containing microneedle array (D-MNA). D-MNA delivers the chemotherapeutic agent transdermally at the site of the lesionto eradicate tumor cells.